HAEMONETICS (HAE) Company Report

Haemonetics (HAE) reported Q2 2026 revenue of $327 million, reflecting a 5% reported decline but 9% organic growth ex CSL, and adjusted EPS of $1.27, an increase of 13%.
The company raised its full-year fiscal 2026 adjusted EPS guidance to $4.80-$5.00 per share and its total revenue guidance to a 1%-4% reported decline or 7%-10% organic growth ex CSL.
Adjusted gross margin reached 60.5% in Q2 2026, an expansion of 380 basis points, and adjusted operating margin expanded 250 basis points to 26.7%.
Operating cash flow was $111 million in Q2 2026, a 128% increase, and free cash flow was $89 million. Full-year free cash flow guidance was raised to $170-$210 million.
Plasma revenue grew 19% organically ex CSL in Q2 2026, with its full-year organic growth guidance ex CSL raised to 14%-17%. Hospital revenue grew 4% organically in Q2 2026, with full-year guidance updated to 4%-7% reported and organic growth.

Nov 6, 2025, 1:00 PM

Haemonetics announces Q2 Fiscal 2026 results and updates full-year guidance

HAE

Earnings

Guidance Update

Share Buyback

Haemonetics reported a (5%) decline in Q2 Fiscal 2026 reported revenue to $327.3 million, but achieved 9% organic ex-CSL revenue growth.
The company delivered an Adjusted EPS of $1.27, up 13% Y/Y, and expanded its Adjusted gross margin to 60.5% and Adjusted operating margin to 26.7%.
Cash flow from operating activities increased 128% and free cash flow increased 140% year-over-year in Q2 Fiscal 2026.
Haemonetics updated its full-year Fiscal 2026 guidance, raising the Adjusted EPS outlook to $4.80 - $5.00 and free cash flow to $170 million - $210 million.
The company repurchased 1.4 million shares of common stock for $75 million during the quarter.

Nov 6, 2025, 1:00 PM

Haemonetics Reports Q2 Fiscal 2026 Results and Raises Full-Year Guidance

HAE

Earnings

Guidance Update

Share Buyback

Haemonetics Corporation reported second quarter fiscal 2026 revenue of $327 million, a 5% decrease compared to the prior year, with organic ex-CSL revenue increasing 9.4%.
Adjusted earnings per diluted share for Q2 fiscal 2026 was $1.27, and free cash flow was $89 million.
The company raised its fiscal 2026 guidance for adjusted earnings per diluted share to a range of $4.80 – $5.00 (from $4.70 – $5.00) and free cash flow to $170 million – $210 million (from $160 million – $200 million).
During the second quarter of fiscal 2026, Haemonetics repurchased 1,430,579 shares for $75.0 million as part of its $500.0 million share repurchase program.

Nov 6, 2025, 11:01 AM

Mauna Kea Technologies Announces Q3 2025 Revenue and Financial Update

HAE

Earnings

Revenue Acceleration/Inflection

Legal Proceedings

Mauna Kea Technologies reported Q3 2025 total revenue of €1,935K, representing a +16% increase at constant exchange rates compared to Q3 2024.
U.S. sales surged +31% at constant exchange rates in Q3 2025, marking continuous acceleration and accounting for over 75% of the Group's product sales (excluding licenses). U.S. system sales also doubled year-to-date compared to the same period in 2024.
The company's cash runway extends to the end of November 2025, and it is pursuing a safeguard plan, estimating a need for €5 million until the end of 2026 and €8 million to achieve profitability in 2027. A hearing for the safeguard plan is scheduled for October 27, 2025.
Revenue from Asia was zero in Q3 2025 due to issues with the joint venture in China, while EMEA & RoW business activity grew by +18% at constant exchange rates.

Oct 13, 2025, 3:45 PM

Astria Therapeutics Initiates EU Patient Recruitment for ALPHA-ORBIT Phase III Trial

HAE

New Projects/Investments

Product Launch

Astria Therapeutics has commenced patient recruitment in the European Union (EU) for its Phase III ALPHA-ORBIT trial of navenibart.
Navenibart is an investigational plasma kallikrein inhibitor monoclonal antibody being developed for the treatment of hereditary angioedema (HAE), with potential dosing every three or six months.
The trial, authorized by the European Medicines Agency (EMA), has activated 32 sites across ten EU countries and aims to evaluate the efficacy and safety of navenibart in up to 135 adults and 10 adolescents with HAE Type 1 or Type 2.

Oct 2, 2025, 10:07 PM

Haemonetics Discusses FY25 Performance, FY26 Outlook, and Strategic Priorities

HAE

Guidance Update

Product Launch

Management Change

Haemonetics' plasma segment is a significant growth driver, with guidance for 4%-7% growth for the year (excluding CSL transition), primarily driven by technological improvements and pricing.
The company expects approximately $100 million in CSL revenue for FY25, winding down by the end of the fiscal year, with no anticipated contribution in FY26. Despite this, Haemonetics is on target for $4.60 Earnings Per Share for FY25.
The vascular closure portfolio, particularly MVP and MVP XL, saw 25% growth last quarter, benefiting from the tailwind of PFA technology. The TEG 6s blood management product continues to achieve double-digit growth and holds an 80% market share in a 25% penetrated market.
Haemonetics aims for high 20% margins in FY26, building on the 25.7% margin posted last quarter, driven by gross margin accretion and operating leverage. The company also divested its whole blood business in early January to focus on high-growth, high-margin segments.
Free cash flow guidance was lowered due to aggressive forecasting and working capital investments, but the company expects a "much cleaner story" for FY26 free cash flow conversion.